CenterWatch Monthly profiles the MMRF as one of the nation's five leading venture capitalists in its August 2007 feature, "Venture Philanthropy on the Rise." The article details the MMRF's approach of funding biotech firms to work with the MMRC to expedite drug development in the field of multiple myeloma. Click here to read the article.

The Multiple Myeloma Research Foundation (MMRF) and Multiple Myeloma Research Consortium (MMRC) are pleased to announce the launch of the MMRC Multiple Myeloma Genomics Portal, the world's only myeloma-specific repository of genomic data. The MMRC Multiple Myeloma Genomics Portal provides the scientific community with open access to high-resolution genomic data from the MMRC Multiple Myeloma Genomics Initiative pre-publication and in near real-time. For more information about the MMRC Multiple Myeloma Genomics Portal, click here. To visit the MMRC Multiple Myeloma Genomics Portal, click here.

The MMRC and Proteolix have initiated a multi-center Phase II clinical trial to study Proteolix's potent and selective proteasome inhibitor, carfilzomib®, in patients with relapsed and refractory multiple myeloma. Ten MMRC Member Institutions will participate in the study, under the MMRC leadership of Melissa Alsina, MD, H. Lee Moffitt Cancer Center & Research Institute. The nine additional sites are City of Hope, Emory University, the Cancer Center at Hackensack University Medical Center, Mayo Clinic, Princess Margaret/University Health Network, Saint Vincent's Comprehensive Cancer Center, University of Michigan, and Washington University. For more information, click here.